Page 2 - கோவன் சுகாதாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing. The round was led by Northpond Ventures and Cowen Healthcare Investments, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. In conjunction with the funding, Shaan Gandhi, M.D., D.Phil., director at Northpond Ventures, joined Aro’s board of directors, along with Kevin Raidy, managing partner of Cowen Healthcare Investments. The company intends to use the funds to advance its lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders.

North pondUnited statesSusan dillonKevin raidyIshaan gandhiKaryn oneilIonis pharmaceuticals incJjdc incNorthpond venturesCowen healthcare investmentsJohnson innovationIonis pharmaceuticalsCowen healthcareKaryno neilவடக்கு பாஂட்ஒன்றுபட்டது மாநிலங்களில்